Non-small cell lung cancer
Conditions
Interventions
Icotinib group:None
Osimertinib group:None
Sponsors
Beijing Chest Hospital Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Retrospective analysis of patients undergoing thoracic surgery from January 2020 to June 2023. 2) Male or female, aged >=18 years old. 3) Histologically confirmed non-small cell lung cancer (NSCLC). 4) Stage IA-IIIB according to the 8th edition AJCCTNM staging system. 5) Radical surgical resection (R0) of primary NSCLC by lobectomy, bilobectomy, sublobar resection, pneumonectomy. 6) EGFR sensitive mutations (Ex19del or L858R) were confirmed by tumor tissue detection, and combined mutations of tp53, L861Q, S768I, and G719X were allowed. 7) Receive icotinib (125mgTID) or osimertinib (80mgQD) within 4-12 weeks after surgery for =6 months. 8) Prior adjuvant chemotherapy was allowed (regimen and cycles were recorded).
Exclusion criteria
Exclusion criteria: 1) Had other primary cancers (non-NSCLC) before the search date 2) History of mixed small cell carcinoma and non-small cell carcinoma; 3) Received incomplete resection (R1/R2) 4) There is a history of other primary malignant tumors, including any known or suspected concurrent primary lung cancer, except in the following cases: malignant tumors that have received radical treatment and have no known active disease and a low risk of recurrence for >=5 years before the first administration of the study intervention (except for cured basal cell carcinoma of the skin or cured primary cervical cancer). 5) Combined with other driver mutations (such as ALK, ROS1, MET, 20ins, T790M, etc.); 6) Any systemic anti-cancer treatment (including radiotherapy, immunotherapy, anti-vascular therapy and other EGFR-TKIs treatments) previously received or during adjuvant therapy for non-small cell lung cancer 7) Received neoadjuvant therapy (chemotherapy/targeted therapy/immunotherapy) 8) Imaging before and after adjuvant therapy suggest disease progression, such as residual lesions or recurrence 9) Patients with EGFR mutations first recorded after the search date 10) Patients who had received treatment with icotinib or osimertinib before the search date 11) Situations where key data are missing: such as no TNM staging record, EGFR mutation or pathological report at the time of diagnosis, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year disease-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year disease-free survival rate;2/3 year overall survival rate;Disease-free survival ; | — |
Countries
China
Contacts
Public ContactYanqing Wang
Beijing Chest Hospital Capital Medical University
Outcome results
None listed